This study is currently recruiting participants.
Number
14-CH-0028
Sponsoring Institute
National Institute of Child Health and Human Development (NICHD)
Recruitment Detail
Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 18 Years Max Age: 80 Years
Referral Letter Required
No
Population Exclusion(s)
Children
Keywords
DOTATATE; Cushing's Syndrome; Hypercortisolism
Recruitment Keyword(s)
None
Condition(s)
ACTH; Cushing's Syndrome
Investigational Drug(s)
18F-DOPA 68Ga-DOTATATE
Investigational Device(s)
Intervention(s)
Radiation: DOTATATE PET-CT Radiation: F-DOPA PET CT Radiation: CT scan Diagnostic Test: Routine MRI scan Diagnostic Test: Gated MRI scan Drug: 68Ga-DOTATATE Drug: 18F-DOPA
Supporting Site
National Institute of Child Health and Human DevelopmentNational Institute of Diabetes and Digestive and Kidney Diseases
--Back to Top--
INCLUSION CRITERIA: - Adults with possible ectopic Cushing syndrome -Age 18-80 - Patients must be willing to return to NIH for follow-up studies. EXCLUSION CRITERIA: -Pregnant or lactating women. A pregnancy test is performed in women of childbearing potential (up to age 55) prior to each MRI or study involving radiation, unless they have a history of hysterectomy and/or bilateral oophorectomy. -Children (age less than 18) are excluded. Because ectopic ACTH secretion is rare in this age group, the likelihood of benefit is less and does not balance the risk of radiation. -Very elderly patients (> 90 years) -For the mifepristone studies only: Patients taking medications that alter CYP3A4 activity will not be eligible for the mifepristone study, since this P450 system metabolizes mifepristone. Patients with hypokalemia (K < 3.5 mEq/L), despite medical therapy with replacement or mineralocorticoid antagonists will also be excluded from the mifepristone studies. Such patients may participate in other components of the protocol. Medications affecting CYP3A4 may be adjusted to allow participation in the mifepristone component, with a one week washout period. -The presence of severe active infection. -clinically significantly impaired cardiovascular (e.g. history of abnormally low ejection fraction, the presence of moderate pulmonary fluid overload, and/or blood pressure over 190/100), abnormal coagulation in the absence of medically-indicated treatment (PT and PTT elevated by 30% above the normal values), hematopoietic (hematocrit less than 30%, hemoglobin below 10 g/dl, white count below 3000 K/UL, and platelets below 100,000 K/mm(3)), hepatic (liver enzymes elevated by 4-fold above normal values), or renal function (plasma creatinine level over 2.1). -Based on the clinical judgment of the attending physician, other medical problems may prompt exclusion. -impaired mental capacity or markedly abnormal psychiatric condition that precludes informed consent. -body weight over 136 kg, which is the limit for the tables used in the scanning areas. -combined blood withdrawal during the six weeks preceding the study greater 450 ml. -known allergy to [(111)In-DTPA-D-Phe]-pentetreotide or other somatostatin analogues. -strong evidence for Cushing s disease. This includes those with a central to peripheral ACTH gradient during IPSS or a lesion on pituitary MRI. We anticipate that these exclusion criteria will increase the ratio of patients with ectopic ACTH syndrome to those with Cushing s disease from the usual 1: 8 to 1: 2, thus we would accrue 3 patients to identify one with ectopic ACTH secretion.
- Adults with possible ectopic Cushing syndrome
-Age 18-80
- Patients must be willing to return to NIH for follow-up studies.
EXCLUSION CRITERIA:
-Pregnant or lactating women. A pregnancy test is performed in women of childbearing potential (up to age 55) prior to each MRI or study involving radiation, unless they have a history of hysterectomy and/or bilateral oophorectomy.
-Children (age less than 18) are excluded. Because ectopic ACTH secretion is rare in this age group, the likelihood of benefit is less and does not balance the risk of radiation.
-Very elderly patients (> 90 years)
-For the mifepristone studies only: Patients taking medications that alter CYP3A4 activity will not be eligible for the mifepristone study, since this P450 system metabolizes mifepristone. Patients with hypokalemia (K < 3.5 mEq/L), despite medical therapy with replacement or mineralocorticoid antagonists will also be excluded from the mifepristone studies. Such patients may participate in other components of the protocol. Medications affecting CYP3A4 may be adjusted to allow participation in the mifepristone component, with a one week washout period.
-The presence of severe active infection.
-clinically significantly impaired cardiovascular (e.g. history of abnormally low ejection fraction, the presence of moderate pulmonary fluid overload, and/or blood pressure over 190/100), abnormal coagulation in the absence of medically-indicated treatment (PT and PTT elevated by 30% above the normal values), hematopoietic (hematocrit less than 30%, hemoglobin below 10 g/dl, white count below 3000 K/UL, and platelets below 100,000 K/mm(3)), hepatic (liver enzymes elevated by 4-fold above normal values), or renal function (plasma creatinine level over 2.1).
-Based on the clinical judgment of the attending physician, other medical problems may prompt exclusion.
-impaired mental capacity or markedly abnormal psychiatric condition that precludes informed consent.
-body weight over 136 kg, which is the limit for the tables used in the scanning areas.
-combined blood withdrawal during the six weeks preceding the study greater 450 ml.
-known allergy to [(111)In-DTPA-D-Phe]-pentetreotide or other somatostatin analogues.
-strong evidence for Cushing s disease. This includes those with a central to peripheral ACTH gradient during IPSS or a lesion on pituitary MRI. We anticipate that these exclusion criteria will increase the ratio of patients with ectopic ACTH syndrome to those with Cushing s disease from the usual 1: 8 to 1: 2, thus we would accrue 3 patients to identify one with ectopic ACTH secretion.
Principal Investigator
Referral Contact
For more information: